The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.

Inclusion Criteria:

• Have commercially manufactured brexucabtagene autoleucel that does not meet commercial release criteria but does meet Kite clinical trial release criteria
• Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been post-menopausal for at least 2 years are not considered to be of childbearing potential)
• Deemed medically fit and stable to receive the product per the investigator's evaluation
• Repeat leukapheresis is not feasible per the investigator's assessment
• Be diagnosed with 1 of the approved labeled indications for brexucabtagene autoleucel that is intended for release
• In the Investigator's opinion, there is no satisfactory alternative therapy available to the individual

Exclusion Criteria:

• History of severe immediate hypersensitivity to any drugs or metabolites of similar chemical classes as brexucabtagene autoleucel
• Uncontrolled active infection or inflammation per physician assessment
• Primary central nervous system (CNS) lymphoma